273 related articles for article (PubMed ID: 8478007)
1. Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling.
Vidaud D; Tartary M; Costa JM; Bahnak BR; Gispert-Sanchez S; Fressinaud E; Gazengel C; Meyer D; Goossens M; Lavergne JM
Hum Genet; 1993 Apr; 91(3):241-4. PubMed ID: 8478007
[TBL] [Abstract][Full Text] [Related]
2. Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leyden phenotype).
Reitsma PH; Mandalaki T; Kasper CK; Bertina RM; Briët E
Blood; 1989 Feb; 73(3):743-6. PubMed ID: 2917196
[TBL] [Abstract][Full Text] [Related]
3. Haemophilia B Leyden arising de novo by point mutation in the putative factor IX promoter region.
Royle G; Van de Water NS; Berry E; Ockelford PA; Browett PJ
Br J Haematol; 1991 Feb; 77(2):191-4. PubMed ID: 2004020
[TBL] [Abstract][Full Text] [Related]
4. The putative factor IX gene promoter in hemophilia B Leyden.
Reitsma PH; Bertina RM; Ploos van Amstel JK; Riemens A; Briët E
Blood; 1988 Sep; 72(3):1074-6. PubMed ID: 3416069
[TBL] [Abstract][Full Text] [Related]
5. Point mutations in four hemophilia B patients from China.
Wang NS; Chen SH; Thompson AR
Thromb Haemost; 1990 Oct; 64(2):302-6. PubMed ID: 2270538
[TBL] [Abstract][Full Text] [Related]
6. An A to T transversion at position -5 of the factor IX promoter results in hemophilia B.
Picketts DJ; D'Souza C; Bridge PJ; Lillicrap D
Genomics; 1992 Jan; 12(1):161-3. PubMed ID: 1733855
[TBL] [Abstract][Full Text] [Related]
7. Moderate hemophilia B Leyden: identification by polymerase chain reaction, sequencing, and oligomer restriction.
Coyle TE; Spicer T; Michalovic D; Poiesz BJ
Am J Hematol; 1994 Jul; 46(3):234-40. PubMed ID: 7677806
[TBL] [Abstract][Full Text] [Related]
8. Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter.
Reijnen MJ; Peerlinck K; Maasdam D; Bertina RM; Reitsma PH
Blood; 1993 Jul; 82(1):151-8. PubMed ID: 8324220
[TBL] [Abstract][Full Text] [Related]
9. Factor IX Chongqing: a new mutation in the calcium-binding domain of factor IX resulting in severe hemophilia B.
Wang NS; Zhang M; Thompson AR; Chen SH
Thromb Haemost; 1990 Feb; 63(1):24-6. PubMed ID: 2339358
[TBL] [Abstract][Full Text] [Related]
10. Christmas disease in a Hovawart family resembling human hemophilia B Leyden is caused by a single nucleotide deletion in a highly conserved transcription factor binding site of the
Brenig B; Steingräber L; Shan S; Xu F; Hirschfeld M; Andag R; Spengeler M; Dietschi E; Mischke R; Leeb T
Haematologica; 2019 Nov; 104(11):2307-2313. PubMed ID: 30846504
[TBL] [Abstract][Full Text] [Related]
11. Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis.
Tartary M; Vidaud D; Piao Y; Costa JM; Bahnak BR; Fressinaud E; Congard B; Laurian Y; Meyer D; Lavergne JM
Br J Haematol; 1993 Aug; 84(4):662-9. PubMed ID: 8217825
[TBL] [Abstract][Full Text] [Related]
12. Haemophilia B Leyden: the effect of mutations at position +13 on the liver-specific transcription of the factor IX gene.
Reijnen MJ; Maasdam D; Bertina RM; Reitsma PH
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):341-8. PubMed ID: 8075306
[TBL] [Abstract][Full Text] [Related]
13. Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation.
Picketts DJ; Lillicrap DP; Mueller CR
Nat Genet; 1993 Feb; 3(2):175-9. PubMed ID: 8499951
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden.
Hirosawa S; Fahner JB; Salier JP; Wu CT; Lovrien EW; Kurachi K
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4421-5. PubMed ID: 2352926
[TBL] [Abstract][Full Text] [Related]
15. First case report of hemophilia B Leyden in Japan.
Yamashita A; Nagae C; Mori M; Ashikaga T; Kojima T; Taki M
Int J Hematol; 2017 Jul; 106(1):135-137. PubMed ID: 28168417
[TBL] [Abstract][Full Text] [Related]
16. Age-specific regulation of clotting factor IX gene expression in normal and transgenic mice.
Boland EJ; Liu YC; Walter CA; Herbert DC; Weaker FJ; Odom MW; Jagadeeswaran P
Blood; 1995 Sep; 86(6):2198-205. PubMed ID: 7662969
[TBL] [Abstract][Full Text] [Related]
17. A method to estimate effects of amino acid substitutions in blood coagulation factor IX from hemophilia B patients.
Furutani H
Medinfo; 1995; 8 Pt 2():909. PubMed ID: 8591581
[TBL] [Abstract][Full Text] [Related]
18. Molecular genotyping of the Italian cohort of patients with hemophilia B.
Belvini D; Salviato R; Radossi P; Pierobon F; Mori P; Castaldo G; Tagariello G;
Haematologica; 2005 May; 90(5):635-42. PubMed ID: 15921378
[TBL] [Abstract][Full Text] [Related]
19. A single base pair deletion in the promoter region of the factor IX gene is associated with haemophilia B.
Hall AJ; Chuansumrit A; Peake IR; Winship PR
Thromb Haemost; 1994 Dec; 72(6):799-803. PubMed ID: 7740444
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations.
Picketts DJ; Mueller CR; Lillicrap D
Blood; 1994 Nov; 84(9):2992-3000. PubMed ID: 7949171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
